Neurocrine Biosciences, Inc.

Historical 13F Holders

Symbol
NBIX
CUSIP
64125C109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 64125C109 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 12.1% 4/28/2025
Event 3/31/2025
JPMorgan Chase & Co 13G/A 6.3% 7/27/2026
Event 6/30/2026
Dodge & Cox 13G 5.6% 5/14/2025
Event 3/31/2025
Vanguard Capital Management LLC 13G 5.2% 4/30/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
State Street Corp 13G 4.8% 2/5/2025
Event 12/31/2024
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 48 517 k $72.2 M
2026 Q2 808 124 M $17.2 B
2026 Q1 721 100 M $13.2 B
2025 Q4 759 99.3 M $14.1 B
2025 Q3 674 102 M $14.3 B
2025 Q2 610 99.2 M $12.5 B
2025 Q1 611 96.7 M $10.7 B
2024 Q4 629 94.8 M $12.9 B
2024 Q3 609 95.2 M $11.0 B
2024 Q2 628 98.0 M $13.5 B
2024 Q1 628 100 M $13.8 B
2023 Q4 583 97.5 M $12.8 B
2023 Q3 543 92.3 M $10.7 B
2023 Q2 477 91.7 M $8.68 B
2023 Q1 509 91.5 M $9.23 B
2022 Q4 550 94.0 M $11.2 B
2022 Q3 483 95.5 M $10.1 B
2022 Q2 456 89.8 M $8.75 B
2022 Q1 453 90.5 M $8.47 B
2021 Q4 436 89.8 M $7.65 B
2021 Q3 418 90.3 M $8.66 B
2021 Q2 435 92.2 M $8.98 B
2021 Q1 455 96.1 M $9.34 B
2020 Q4 441 90.6 M $8.70 B
2020 Q3 457 89.9 M $8.65 B
2020 Q2 457 91.6 M $11.2 B
2020 Q1 411 91.6 M $7.93 B
2019 Q4 427 90.1 M $9.68 B
2019 Q3 363 90.8 M $8.18 B
2019 Q2 349 89.8 M $7.58 B
2019 Q1 371 89.5 M $7.88 B
2018 Q4 367 91.9 M $6.58 B
2018 Q3 384 91.7 M $11.3 B
2018 Q2 304 92.6 M $9.10 B
2018 Q1 293 93.3 M $7.73 B
2017 Q4 286 94.1 M $7.30 B
2017 Q3 241 96.1 M $5.89 B
2017 Q2 245 94.9 M $4.36 B
2017 Q1 239 85.1 M $3.68 B
2016 Q4 249 84.4 M $3.27 B
2016 Q3 264 85.7 M $4.34 B
2016 Q2 254 85.0 M $3.86 B
2016 Q1 231 87.6 M $3.46 B
2015 Q4 238 84.5 M $4.78 B
2015 Q3 227 88.6 M $3.57 B
2015 Q2 209 83.4 M $3.98 B
2015 Q1 190 85.2 M $3.38 B
2014 Q4 153 75.3 M $1.68 B
2014 Q3 152 73.4 M $1.15 B
2014 Q2 143 71.1 M $1.06 B
2014 Q1 136 69.8 M $1.12 B